

Shingles Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Market Report | 2024-11-22 | 130 pages | Global Market Insights

AVAILABLE LICENSES:

- Single User \$4850.00
- Multi User \$6050.00
- Enterprise User \$8350.00

Report description:

The Global Shingles Vaccine Market was valued at USD 4.9 billion in 2024 and is projected to grow at a robust CAGR of 10.1% from 2025 to 2034. Key factors driving this growth include the increasing aging population, improved reimbursement frameworks, and heightened awareness about shingles prevention and complications.

Efforts to educate the public about shingles risks, particularly among older adults, have significantly boosted vaccine adoption. Health organizations are emphasizing the benefits of vaccination in mitigating severe complications, including chronic pain. These campaigns encourage proactive health measures, particularly among the elderly and their caregivers, further fueling the market expansion.

Public health campaigns and educational programs have significantly increased awareness of the risks posed by shingles, especially among older adults. Health organizations are proactively highlighting the importance of vaccination in preventing the disease and minimizing the chances of chronic pain. Consequently, a growing number of elderly individuals and their caregivers are choosing vaccination as a preventive healthcare step, driving the expansion of the shingles vaccine market.

The market is segmented by product into Shingrix, Zostavax, and SKYZoster, with Shingrix leading the market by generating USD 4.2 billion in revenue in 2024. Its recombinant formulation provides durable and effective protection, particularly for high-risk groups such as older adults. The vaccine's long-lasting immunity reduces the need for frequent boosters, enhancing its appeal as a cost-effective and reliable option.

By vaccine type, the market is categorized into recombinant and live attenuated vaccines. The recombinant vaccine segment dominated in 2024 and is forecasted to reach USD 11.3 billion by 2034. These vaccines demonstrate superior efficacy, offering 90% protection even among vulnerable populations. Their extended immunity duration eliminates the need for repeated doses, making them the preferred choice over live attenuated options.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

North America shingles vaccine market generated USD 2.7 billion in 2024. This dominance is driven by high awareness levels, supportive healthcare policies, and strong public health advocacy. Recommendations for shingles vaccination for adults aged 50 and older have been widely adopted, supported by accessible insurance coverage through Medicare and private insurers. The aging demographic and proactive health initiatives further strengthen the region's market position.

Table of Contents:

Report Content

Chapter 1 Methodology and Scope

1.1 Market scope and definitions

1.2 Research design

1.2.1 Research approach

1.2.2 Data collection methods

1.3 Base estimates and calculations

1.3.1 Base year calculation

1.3.2 Key trends for market estimation

1.4 Forecast model

1.5 Primary research and validation

1.5.1 Primary sources

1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Rising geriatric population

3.2.1.2 Advancements in vaccine development

3.2.1.3 Favourable reimbursement policies

3.2.1.4 Growing awareness about shingles and its complications

3.2.2 Industry pitfalls and challenges

3.2.2.1 Stringent regulatory requirements

3.3 Growth potential analysis

3.4 Regulatory landscape

3.5 Pricing analysis, 2023

3.6 Pipeline analysis

3.7 Technology landscape

3.8 Future market trends

3.9 Gap analysis

3.10 Porter's analysis

3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction

4.2 Company matrix analysis

4.3 Competitive analysis of major market players

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.4 Competitive positioning matrix

4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 (\$ Mn)

5.1 Key trends

5.2 Shingrix

5.3 Zostavax

5.4 SKYZoster

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 (\$ Mn)

6.1 Key trends

6.2 Recombinant vaccine

6.3 Live attenuated vaccine

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 (\$ Mn)

7.1 Key trends

7.2 North America

7.2.1 U.S.

7.2.2 Canada

7.3 Europe

7.3.1 Germany

7.3.2 UK

7.3.3 France

7.3.4 Spain

7.3.5 Italy

7.3.6 Netherlands

7.4 Asia Pacific

7.4.1 China

7.4.2 Japan

7.4.3 India

7.4.4 Australia

7.4.5 South Korea

7.5 Latin America

7.5.1 Brazil

7.5.2 Mexico

7.5.3 Argentina

7.6 Middle East and Africa

7.6.1 South Africa

7.6.2 Saudi Arabia

7.6.3 UAE

Chapter 8 Company Profiles

8.1 GSK plc

8.2 Merck & Co.

8.3 SK bioscience

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Shingles Vaccine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

Market Report | 2024-11-22 | 130 pages | Global Market Insights

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4850.00
	Multi User	\$6050.00
	Enterprise User	\$8350.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com